(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202309 | 202209 | % Var | 202309 | 202209 | % Var | 202303 | 202203 | % Var | |
| Sales | 0.84 | 0.68 | 23.53 | 1.52 | 2.76 | -44.93 | 10.19 | 3.65 | 179.18 |
| Other Income | 5.27 | 4.32 | 21.99 | 9.84 | 8.73 | 12.71 | 17.51 | 19.19 | -8.75 |
| PBIDT | 3.11 | 2.28 | 36.40 | 4.95 | 5.16 | -4.07 | 10.60 | 10.25 | 3.41 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBDT | 3.11 | 2.28 | 36.40 | 4.95 | 5.16 | -4.07 | 10.60 | 10.25 | 3.41 |
| Depreciation | 0.24 | 0.23 | 4.35 | 0.48 | 0.46 | 4.35 | 0.94 | 0.92 | 2.17 |
| PBT | 2.87 | 2.05 | 40.00 | 4.47 | 4.70 | -4.89 | 9.66 | 9.33 | 3.54 |
| TAX | 0.91 | 0.70 | 30.00 | 1.96 | 1.40 | 40.00 | 4.63 | 4.57 | 1.31 |
| Deferred Tax | 0.10 | -0.30 | -133.33 | 0.70 | 0.40 | 75.00 | 2.12 | 0.22 | 863.64 |
| PAT | 1.96 | 1.35 | 45.19 | 2.51 | 3.30 | -23.94 | 5.03 | 4.76 | 5.67 |
| Equity | 49.96 | 49.96 | 0.00 | 49.96 | 49.96 | 0.00 | 49.96 | 49.96 | 0.00 |
| PBIDTM(%) | 370.24 | 335.29 | 10.42 | 325.66 | 186.96 | 74.19 | 104.02 | 280.82 | -62.96 |
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1671.05 |
| Dr. Reddys Lab | 1229.60 |
| Cipla | 1236.50 |
| Zydus Lifesciences | 945.00 |
| Lupin | 2307.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: